Condensed Interim Consolidated Financial Statements (Expressed in United States dollars)



QUEEN'S ROAD CAPITAL INVESTMENT LTD.

Three and nine months ended May 31, 2025

(Unaudited)

Condensed Interim Consolidated Statements of Financial Position (expressed in thousands of United States dollars)

	Notes		May 31, 2025		August 31, 2024
	NOLES		(Unaudited)		(Audited)
Assets					
Current assets:					
Cash and cash equivalents		\$	1,913	\$	1,094
Prepaids and deposits			169		126
Receivables	3		5,291		2,196
			7,373		3,416
Non-current assets:					
Investments	4		313,503		279,332
Right-of-use assets			515		108
			314,018		279,440
Liabilities and Shareholders' Equity		\$	321,391	\$	282,856
Liabilities and Shareholders' Equity Current liabilities: Accounts payable and accrued liabilities Borrowings	6 8	\$ \$	321,391 837 26,540	\$	282,856 1,106 31,626
Current liabilities: Accounts payable and accrued liabilities	6		837	·	1,106
Current liabilities: Accounts payable and accrued liabilities Borrowings Lease liabilities	6		837 26,540	·	1,106 31,626
Current liabilities: Accounts payable and accrued liabilities Borrowings Lease liabilities Non-current liabilities:	6		837 26,540 <u>170</u> 27,547	·	1,106 31,626 126
Current liabilities: Accounts payable and accrued liabilities Borrowings Lease liabilities	6		837 26,540 170	·	1,106 31,626 126
Current liabilities: Accounts payable and accrued liabilities Borrowings Lease liabilities Non-current liabilities: Long-term lease liabilities	6		837 26,540 170 27,547 344	·	1,106 31,626 126 32,858 -
Current liabilities: Accounts payable and accrued liabilities Borrowings Lease liabilities Non-current liabilities:	6		837 26,540 170 27,547 344	·	1,106 31,626 126 32,858 -
Current liabilities: Accounts payable and accrued liabilities Borrowings Lease liabilities Non-current liabilities: Long-term lease liabilities Shareholders' equity:	6		837 26,540 170 27,547 344 27,891	·	1,106 31,626 126 32,858 - 32,858
Current liabilities: Accounts payable and accrued liabilities Borrowings Lease liabilities Non-current liabilities: Long-term lease liabilities Shareholders' equity: Share capital	6		837 26,540 170 27,547 344 27,891 201,243	·	1,106 31,626 126 32,858 - 32,858 177,327
Current liabilities: Accounts payable and accrued liabilities Borrowings Lease liabilities Non-current liabilities: Long-term lease liabilities Shareholders' equity: Share capital Reserves	6		837 26,540 170 27,547 <u>344</u> 27,891 201,243 16,196	·	1,106 31,626 126 32,858 - 32,858 177,327 19,651

See accompanying notes to these condensed interim consolidated financial statements.

Approved on behalf of the Board:

/s/	Warren	Gilman
-----	--------	--------

Director

/s/ Alex Granger

Director

Condensed Interim Consolidated Statements of Income and Comprehensive Income (expressed in thousands of United States dollars, except share and per share numbers)

		_	Three mor	ths e	ended	 Nine mon	ths e	nded
			May 31,		May 31,	May 31,		May 31
Not	es		2025		2024	2025		2024
			(Unaudited)		(Unaudited)	(Unaudited)		(Unaudited)
Income from investments:								
Interest and other income	4	\$	4,893	\$	3,664	\$ 13,925	\$	10,529
Establishment fee income	4		150		-	900		3,000
Realized gain (loss) from investments Unrealized gain from	4		1,760		(3,709)	3,456		5,802
investments	4		33,731		31,678	15,774		62,345
Total income from investments			40,534		31,633	34,055		81,676
Operating expenses:					107	0 //		
Business development and marketing			68		105	214		275
Depreciation Foreign exchange (gain) loss			46 (66)		47 14	139 116		140 88
Management and director fees	7		(00) 496		488	1.489		1.425
Office and administration	'		82		71	247		216
Professional and regulatory fees			81		127	411		305
Total operating expenses			707		852	2,616		2,449
Income before interest synapses								
Income before interest expense and income taxes			39,827		30,781	31,439		79,227
Interest expense	5		351		628	1,176		1,179
Income before income taxes			39,476		30,153	30,263		78,048
Income taxes			(12)		-	(7)		
Net income and comprehensive								
income		\$	39,488	\$	30,153	\$ 30,270	\$	78,048
Net income per common share:								
	10		\$0.81		\$0.66	\$0.62		\$1.72
Diluted	10		\$0.76		\$0.61	\$0.58		\$1.58
Weighted average number of								
common shares:	10		40.000.004		45 000 050	40.005.700		
Basic	10 10		48,966,391		45,603,950	48,885,762		45,445,661
Diluted	10		51,694,791		49,468,950	52,260,164		49,310,661

See accompanying notes to these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (expressed in thousands of United States dollars, except share numbers)

For the nine months ended May 31, 2025 and 2024 (Unaudited)

	Notes	lssued number of shares ⁽¹⁾	Share capital		Treasury shares		Reserves		Retained earnings	Shareholders' equity
Balance, August 31, 2024		45,548,550 \$	177,327	\$	-	\$	19,651	\$	53,020	\$ 249,998
Shares issued – private placement	9(a)	2,142,857	11,025	Ψ	-	Ψ	- 13,001	Ψ		φ <u>2</u> 43,330 11,025
Shares issued – options exercised	9(a)	1,136,600	7,801		-		(3,455)		-	4,346
Shares issued - dividend reinvestment plan	9(a)	1,135,253	5,653		-		(0,100)		(5,653)	-
Shares rounded up on consolidation	9(a)	3	- 0,000		-		-		(0,000)	-
Shares repurchased	9(a)	-	-		(634)		-		-	(634)
Shares canceled	9(a)	(139,013)	(563)		634		-		(71)	(001)
Dividend - paid in cash	9(e)	-	(-		-		(1,505)	(1,505)
Net income		-	-		-		-		30,270	30,270
Balance, May 31, 2025		49,824,250 \$	201,243	\$	-	\$	16,196	\$	76,061	\$ 293,500
Balance, August 31, 2023		45,035,651 \$	174,779	\$	-	\$	19,651	\$	41,518	\$ 235,948
Shares issued - dividend reinvestment plan	9(a)	665,296	3,144		-		-		(3,144)	-
Shares repurchased	9(a)	-	-		(752)		-		-	(752)
Shares canceled	9(a)	(126,129)	(493)		752		-		(259)	-
Dividend - paid in cash	9(e)	-	-		-		-		(3,074)	(3,074)
Net income		-	-		-		-		78,048	78,048
Balance, May 31, 2024		45,574,818 \$	177,430	\$	-	\$	19,651	\$	113,089	\$ 310,170

See accompanying notes to these condensed interim consolidated financial statements.

⁽¹⁾ The Company implemented a consolidation of its common shares in January 2025 and the number of common shares has been retrospectively adjusted. Refer to Note 1 for further information.

Condensed Interim Consolidated Statements of Cash Flows (expressed in thousands of United States dollars)

		 Nine mo	onths	ended
	Notes	May 31, 2025		May 31, 2024
	Notes	(Unaudited)		(Unaudited)
Cash flows provided by (used in):				
Operating activities:				
Net income		\$ 30,270	\$	78,048
Items not affecting cash:				
Interest income on convertible debentures	4(c)	(13,873)		(10,335)
Other income	4(c)	(52)		(194)
Establishment fee income	4(c)	(300)		(2,100)
Realized gain on investments	4	(3,456)		(5,802)
Unrealized gain on investments	4	(15,774)		(62,345)
Depreciation		139		140
Interest expense on borrowings and amortization				
of transaction costs	5	1,170		1,170
Interest expense on lease liabilities	5	6		9
Income tax recovery		(7)		-
Unrealized foreign exchange loss		41		28
Interest received on convertible debentures	4(c)	8,374		5,752
Other interest and dividend income received	4(c)	52		194
Interest expense paid on borrowings	8	(1,214)		(636)
Interest expense paid on lease liabilities		(6)		(9)
Income taxes paid		(18)		(117)
		5,352		3,803
Changes in working capital items:				
Other receivables		(751)		466
Prepaid expenses and advances		(43)		(44)
Accounts payable and accrued liabilities		(244)		(142)
Cash flows provided by operating activities		4,314		4,083
Financing activities:				
Common shares issued – private placement	9(a)	11,025		-
Common shares issued – options	9(a)	4,346		-
Common shares repurchased	9(a)	(634)		(752)
Dividends paid	9(e)	(1,505)		(3,074)
Payment of lease liabilities		(158)		(138)
Borrowings drawn, net of transaction costs	8	35,055		22,175
Borrowings repaid	8	(40,097)		-
Cash flows provided by financing activities		8,032		18,211
Investing activities:				
Acquisition of investments	4	(30,000)		(100,000)
Proceeds from sale of equity and other investments	4	18,514		69,400
Cash flows used in investing activities		(11,486)		(30,600)
Increase (decrease) in the period		860		(8,306)
Cash, beginning of the period		1,094		14,745
Effect of currency translation on cash				
		(41)		(27)
Cash, end of the period		\$ 1,913	\$	6,412

Supplemental disclosure with respect to cash flows

13

See accompanying notes to these condensed interim consolidated financial statements.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

1. Reporting entity and nature of operations:

Queen's Road Capital Investment Ltd. ("QRC" or the "Company") is a dividend paying, resource focused investment company, making investments in privately held and publicly traded resource companies. The Company acquires and holds securities for long-term capital appreciation, with a focus on convertible debt securities of issuers having resource projects in advanced development or production located in safe jurisdictions.

The Company was incorporated under the laws of the Province of British Columbia, Canada on January 25, 2011. On January 29, 2020, the Company redomiciled from British Columbia, Canada to the Cayman Islands. The Company's corporate office is located at Suite 2006, 2 Queen's Road Central, Hong Kong. The Company is listed on the Toronto Stock Exchange ("TSX") and the trades under the symbol "QRC".

On January 10, 2025, the Company's Board of Directors approved the consolidation of the Company's issued and outstanding common shares at a consolidation ratio of ten (10) preconsolidation common shares for every post-consolidation common share (the "Share Consolidation"). Outstanding stock options were similarly adjusted by the Share Consolidation ratio. The Share Consolidation resulted in 490,401,845 pre-consolidated common shares on January 10, 2025 being consolidated into 49,040,187 post-consolidation common shares on January 15, 2025. The Share Consolidation was implemented with effect from January 15, 2025. In accordance with IFRS Accounting Standards, the change has been applied retrospectively and as a result disclosures of common shares, per common share data and data related to stock options in the accompanying condensed interim consolidated financial statements and related notes reflect this Share Consolidation for all periods presented unless otherwise specified.

2. Basis of presentation:

(a) Statement of compliance:

These condensed interim consolidated financial statements have been prepared in accordance with IAS 34, *Interim Financial Reporting* and using the accounting policies, determination of significant estimates and judgments, and corresponding accounting treatments consistent with the Company's Consolidated Financial Statements for the year ended August 31, 2024. These condensed interim consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended August 31, 2024.

These condensed interim consolidated financial statements were authorized for issue by the Board of Directors of the Company on July 11, 2025.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

2. Basis of presentation (continued):

(b) Basis of presentation:

These condensed interim consolidated financial statements have been prepared on a historical cost convention, except for financial instruments carried at fair value through profit or loss ("FVTPL") and share-based compensation recognized at fair value at the measurement date. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

The condensed interim consolidated financial statements present amounts in thousands of United States dollars (\$), except for disclosures of common shares, per common share data, and data related to stock options or where otherwise stated. All figures have been rounded to the nearest thousand.

3. Receivables:

Receivables consist of the following:

	May 31, 2025	August 31, 2024
Interest receivable on convertible debentures Due from a related party (note 7)	\$ 4,540 751	\$ 2,196 -
	\$ 5,291	\$ 2,196

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments:

The Company had the following investments in listed and unlisted entities stated at estimated fair value:

			May 31, 2025		August 31, 2024
Equity investments:					
NexGen Energy Ltd. ⁽¹⁾	(2)	\$	65,122	\$	64,170
	(a)	φ	,	φ	,
Other equity investments	(b)		33,862		27,437
			98,984		91,607
Convertible debentures:	(c)				
Challenger Gold Ltd.			12,303		10,515
Contango ORE, Inc.			16,261		17,222
Gold Royalty Corp.			35,173		28,184
IsoEnergy Ltd. ⁽²⁾			12,116		24,726
Los Andes Copper Ltd.			10,876		11,094
Moxico Resources plc ⁽³⁾			49,989		18,162
NexGen Energy Ltd. ⁽¹⁾			77,801		77,822
			214,519		187,725
		\$	313,503	\$	279,332

(1) On September 28, 2023, the Company converted the NexGen Energy Ltd. ("NexGen") debentures issued in 2020 into 8,663,461 common shares of NexGen at a conversion price of C\$2.34 per share. On September 22, 2023, the Company purchased \$70,000 of new debentures issued by NexGen with a maturity date of September 22, 2028.

(2) On January 27, 2025, the Company converted \$3,000 of the \$6,000 IsoEnergy Ltd. ("IsoEnergy") debentures issued in 2020 into 4,887,273 common shares of IsoEnergy at a conversion price of C\$0.88 per share.

(3) The Company purchased debentures issued by Moxico Resources plc ("Moxico"): \$20,000 on July 17, 2024; \$10,000 on October 21, 2024; \$10,000 on December 6, 2024; \$5,000 on February 18, 2025 and US\$5,000 on April 1, 2025. These debentures all form part of the same debentures issued with a maturity date of July 17, 2029.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments (continued):

The continuity of the Company's investments during the nine months ended May 31, 2025, is as follows:

	August 31, 2024	Additions ⁽¹⁾	Net proceeds from disposition	(2)	Realized gain (loss)	Unrealized gain	May 31, 2025
Equity investments Convertible debentures	\$ 91,607 187,725	\$ 13,145 30,000	\$ (18,514) (9,690)	\$	4,164 (708)	\$ 8,582 7,192	\$ 98,984 214,519
	\$ 279,332	\$ 43,145	\$ (28,204)	\$	3,456	\$ 15,774	\$ 313,503

- ⁽¹⁾ Additions of equity and other investments of \$13,145 comprise \$9,690 IsoEnergy common shares received on the conversion of \$3,000 of the IsoEnergy 2020 debentures on January 27, 2025, \$3,155 investments received for the settlement of interest receivable and \$300 investments received for the settlement of establishment fees (note 13). Additions of convertible debentures of \$30,000 comprise Moxico debentures of \$10,000 purchased on October 21, 2024; \$10,000 on December 6, 2024; \$5,000 on February 18, 2025, and \$5,000 purchased on April 1, 2025.
- ⁽²⁾ Net proceeds from disposition of equity and other investments of \$18,514 comprise proceeds from the sale of other equity investments. Net proceeds from disposition of convertible debentures of \$9,690 comprised the value of the common shares received on the conversion of \$3,000 of the IsoEnergy 2020 debentures on January 27, 2025 (note 13).

The continuity of the Company's investments during the nine months ended May 31, 2024, is as follows:

	August 31, 2023	Additions ⁽¹⁾	Net proceeds from disposition ⁽²	2)	Realized gain	Unrealized gain	May 31, 2024
Equity and other investments Convertible debentures	\$ 80,768 139,831	\$ 81,495 100,000	\$ (69,400) \$ (77,445)	5	1,605 4,197	\$ 26,552 35,793	\$ 121,020 202,378
	\$ 220,599	\$ 181,495	\$ (146,845) \$;	5,802	\$ 62,345	\$ 323,398

⁽¹⁾ Additions of equity and other investments of \$81,495 comprise \$53,935 NexGen common shares received on conversion of the NexGen 2020 debentures on September 28, 2023; \$23,510 Adriatic common shares received on conversion of the Adriatic debentures on March 1, 2024; \$2,100 investments received for the settlement of establishment fees and \$1,951 investments received for the settlement of interest receivable (note 13). Additions of convertible debentures \$100,000 comprise \$70,000 NexGen debentures purchased on September 23, 2023, and \$30,000 Gold Royalty debentures purchased on December 15, 2023.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments (continued):

⁽²⁾ Net proceeds from the disposition of equity and other investments of \$69,400 comprise \$45,240 from the sale of NexGen shares to WSHP (note 4(a)), \$14,806 from the redemption of Osisko Green Acquisition Ltd. Class A common shares, and \$9,354 proceeds from the sale of other equity investments. Net proceeds from the disposition of convertible debentures of \$77,445 comprise \$53,935 NexGen common shares received on the conversion of the NexGen 2020 debentures on September 28, 2023, and \$23,510 Adriatic common shares received on the conversion of the Adriatic debentures on March 1, 2024 (note 13).

The continuity of the Company's investments during the three months ended May 31, 2025, is as follows:

	February 29, 2025	Additions ⁽¹⁾	Net proceeds from disposition	(2)	Realized gain	Unrealized gain	May 31, 2025
Equity investments Convertible debentures	\$ 89,241 190,745	\$ 921 5,000	\$ (7,895)	\$	1,760 -	\$ 14,957 18,774	\$ 98,984 214,519
	\$ 279,986	\$ 5,921	\$ (7,895)	\$	1,760	\$ 33,731	\$ 313,503

⁽¹⁾ Additions of equity and other investments of \$921 comprise \$771 investments received for the settlement of interest receivable and \$150 investments received for the settlement of establishment fees. Additions of convertible debentures comprise \$5,000 Moxico debentures on April 1, 2025.

⁽²⁾ Net proceeds from the disposition of equity and other investments of \$7,895 comprise proceeds from the sale of other equity investments.

The continuity of the Company's investments during the three months ended May 31, 2024, is as follows:

	February 29, 2024	Additions ⁽¹⁾	Net proceeds from disposition	Realized gain (loss)	Unrealized gain	May 31, 2024
Equity and other investments Convertible debentures	\$ 83,089 213,078	\$ 24,015 -	\$ (1,244) (23,510)	\$ 451 (4,160)	\$ 14,709 16,969	\$ 121,020 202,378
	\$ 296,167	\$ 24,015	\$ (24,754)	\$ (3,709)	\$ 31,678	\$ 323,398

(1) Additions of equity and other investments of \$24,015 comprise \$23,510 Adriatic common shares received on conversion of the Adriatic debentures on March 1, 2024, and \$505 investments received for the settlement of interest receivable.

⁽²⁾ Net proceeds from disposition of equity and other investments of \$1,244 comprise proceeds from the sale of other equity investments. Net proceeds on the disposition of convertible debentures of \$23,510 comprise the Adriatic common shares received on the conversion of the Adriatic debentures on March 1, 2024.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments (continued):

The realized gain from financial instruments at FVTPL represents the difference between the carrying amount of the financial instrument at the beginning of the reporting period, or the transaction price if it was purchased in the current reporting period, and the consideration received on disposal.

The unrealized gain or loss represents the difference between the carrying amount of a financial instrument at the beginning of the period, or the transaction price if it was purchased in the current reporting period, and its carrying amount at the end of the reporting period.

(a) Investment in NexGen Energy Ltd. ("NexGen") common shares:

On May 27, 2020, the Company purchased 11,611,667 common shares of NexGen, a company related by way of two common directors, at \$1.29 per share for a purchase price of \$15,000. On September 22, 2023, the Company sold 8,700,000 common shares of NexGen to Washington H. Soul Pattinson and Company Ltd. ("WHSP") at \$5.20 for a cash consideration of \$45,240 and sold an additional 900,000 shares to other parties during the year ended August 31, 2024.

On September 28, 2023, the Company converted its existing \$15,000 convertible debenture issued by NexGen on May 27, 2020, (the "NexGen 2020 Debentures") into 8,663,461 common shares of NexGen, at a conversion share price of C\$2.34. The fair value of the conversion shares, based on the closing market price on the conversion date, was \$53,934.

The fair value of the NexGen 10,675,128 common shares held at May 31, 2025, is \$65,122 (August 31, 2024 - 10,675,128 NexGen common shares at fair value \$64,170). The fair value of each common share is estimated using the closing market price on the relevant date.

(b) Other investments held for investment purposes:

The Company holds common shares in listed and unlisted entities. The shares are held as a result of (a) establishment fees settled in common shares related to convertible debenture investments; (b) interest income on convertible debenture investments settled in common shares; (c) common shares held from conversion of convertible debenture investments; and/or (d) purchases of common shares for investment purpose.

The estimated fair value of other equity investments at May 31, 2025, is \$33,862 (August 31, 2024 - \$27,437).

The fair value for shares traded on a stock market is estimated using the closing market price of the shares on the relevant date. The fair value for equity investments which are not traded on a stock market is estimated using the closing market price of an equivalent traded instrument with an appropriate discount applied to reflect the restrictions or different nature of the investment or other third-party evidence.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments (continued):

(c) Investments in convertible debentures:

The Company holds unsecured convertible debentures issued by listed and unlisted entities. Details of investments in debentures held are in the table below, with further information in the footnotes:

Issuer	Principal ⁽¹⁾ US\$000	Issue date ⁽²⁾	Maturity date	Annual coupon	Annual coupon settled by	Conversion price ⁽³⁾	Redemption
Challenger Gold Ltd. ("Challenger") ⁽⁴⁾	15,000	September 12, 2022	September 12, 2026	9.0%	Cash 7.0% Shares 2.0%	A\$0.25	(6)
Contango ORE, Inc. ("Contango") ⁽⁴⁾	20,000	April 26, 2022	May 26, 2028 ⁽⁷⁾	9.0% (7)	Cash 7.0% Shares 2.0%	\$30.50	(6)
Gold Royalty Corp. ("Gold Royalty") ⁽⁴⁾	30,000	December 15, 2023	December 15, 2028	10.0%	Cash 7.0% Shares 3.0%	\$1.90 ⁽⁸⁾	(8)
IsoEnergy Ltd. ("IsoEnergy") ⁽⁴⁾	Various 3,000to 4,000 ⁽⁹⁾	Various (2020 to 2022)	Various (2025 to 2027)	8.5% ⁽⁹⁾ to 10%	Cash 6.0% ⁽⁹⁾ to 7.5% Shares 2.5% ⁽⁹⁾	(9)	(6), (9)
Los Andes Copper Ltd. ("Los Andes") ⁽⁴⁾	Various 4,000 to 5,000	Various (2021 to 2022)	Various (2026 to 2027)	8.0%	Cash 5.0% ⁽¹⁰⁾ Shares 3.0% ⁽¹⁰⁾	(10)	(6)
Moxico Resources plc ("Moxico") ⁽⁵⁾	50,000	July 17,2024 ⁽¹	¹⁾ Jul 17, 2029	11.0%	Cash 7.5% ⁽¹¹⁾ Shares 3.5% ⁽¹¹⁾	GBP0.90 ⁽¹¹⁾	(11)
NexGen Energy Ltd. ("NexGen") ⁽⁴⁾	70,000	September 22, 2023	September 22, 2028	9.0%	Cash 6.0% Shares 3.0%	US\$6.76	(6)

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4 Investments (continued):

(c) Investments in convertible debentures (continued):

Notes:

- (1) The convertible debentures are unsecured and rank equally in right of payment with all present and future unsecured and unsubordinated indebtedness of the issuer.
- (2) The Company was paid an establishment fee equal to 3% of the principal amount of the convertible debentures on issue date, settled either in cash or common shares of the issuer.
- (3) The Company is entitled to convert, from time to time prior to the maturity date, some or all of the outstanding principal amount into common shares at the conversion price.
- (4) Listed entity.
- (5) Unlisted entity.
- (6) Issuers have certain redemption rights after the 3-anniversary of the issue date for a convertible debenture if the weighted average trading price of the relevant stock is above a pre-determined percentage of the conversion price, together with redemption rights on certain defined change of control events.
- (7) *Contango*: The maturity date was extended from April 26, 2026 to May 26, 2028 and the annual coupon increased from 8.0% to 9.0% on May 17, 2023.
- (8) Gold Royalty: The Company is entitled to convert, from time to time prior to the maturity date, some or all of the outstanding principal amount into common shares at the conversion price of \$1.90. The issuer can redeem the debenture between December 15, 2026 and December 29, 2026. If the issuer gives notice of redemption during this period, the Company can exercise its right to convert some or all of the outstanding principal at a conversion price of \$1.75 between December 15, 2026, to January 6, 2027. The issuer also has redemption rights on certain defined change of control events.
- (9) IsoEnergy: The annual coupon on the \$6,000 debentures issued in 2020 reduces from 8.5% to 7.5%, reducing the cash and common share interest from 6.0% and 2.5% to 5.0% and 2.5%, respectively, on filing of an economically positive preliminary assessment compliant with the requirements of National Instrument 43-101 of the Canadian Securities Commission. This filing has not been made as at May 31, 2025 or August 31, 2024.

Conversion prices ranged from C\$0.88 to C\$4.33. On March 20, 2025 the conversion prices were adjusted to range from C\$3.52 to C\$17.32 to reflect a four to one share consolidation completed by IsoEnergy.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments (continued):

(c) Investments in convertible debentures (continued):

Notes (continued):

On January 27, 2025, the Company converted \$3,000 of the \$6,000 debentures issued in 2020 into 4,887,273 common shares of IsoEnergy, at a conversion share price of C\$0.88. The fair value of the conversion shares, based on the closing market price on the conversion date, was \$9,690.

- (10) Los Andes: Interest can be settled by between 5% to 8% per annum in cash and between 0% and 3% per annum in shares at the election of the issuer. Conversion prices range from C\$10.82 to C\$19.67.
- (11) Moxico: The Company purchased \$20,000 debentures on July 17, 2024, \$10,000 debentures on October 21, 2024, \$10,000 debentures on December 6, 2024, \$5,000 on February 18, 2025, and \$5,000 on April 1, 2025. These debentures all form part of the same debentures with a maturity date of July 17, 2029. Interest can be settled by between 7.5% to 11% per annum in cash and between 0% and 3.5% per annum in shares at the election of the issuer. The Company is entitled to convert, from time to time, prior to the maturity date, some or all of the outstanding principal amount into common shares at the conversion price of GBP0.90. The issuer can redeem the debenture between July 17, 2027, and July 31, 2027. If the issuer gives notice of redemption during this period, the Company can exercise its right to convert some or all of the outstanding principal at a conversion price of GBP0.83 between July 17, 2027, to July 31, 2027. The issuer also has redemption rights on certain defined change of control events.

During the nine months ended May 31, 2025, the Company received establishment fees of \$900 on convertible debentures of \$30,000 issued by Moxico, \$600 settled in cash and \$300 settled in common shares of Moxico. During the nine months ending May 31, 2024, the Company received establishment fees of \$2,100 on convertible debentures of \$70,000 issued by NexGen, settled in common shares, and \$900 on convertible debentures of \$30,000 issued by Gold Royalty, settled in cash.

The estimated fair value of convertible debentures at May 31, 2025, is \$214,519 (August 31, 2024 - \$187,725). The fair value for convertible debentures is estimated pursuant to IFRS 13, *Fair Value Measurement*, using valuation models based on a system of two coupled Black-Scholes Option Pricing equations and partial differential equations that are solved simultaneously using finite-difference methods.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments (continued):

(c) Investments in convertible debentures (continued):

The assumptions and inputs below were used in the models for debentures held by the Company:

May 31, 2025	Challenger	Contango	Gold Royalty	IsoEnergy (4)	Los Andes ⁽⁴⁾	Moxico	NexGen
Expected life (years)	1.3	3.0	3.5	0.2 to 2.5	1.0 to 2.3	4.1	3.3
Market price volatility ⁽¹⁾	73%	64%	56%	64% to 84%	49% to 56%	58%	58%
Modeled price volatility ⁽²⁾	64%	47%	36%	54% to 84%	43% to 54%	36%	40%
Risk-free interest rate	3.4%	4.0%	4.0%	2.4% to 2.6%	2.5% to 2.6%	4.1%	4.0%
Coupon interest rate	9.0%	9.0%	10.0%	8.5% to 10.0%	8.0%	11.0%	9.0%
Expected dividend yield	-%	-%	-%	-%	-%	-%	-%
Credit spread	30%	31%	22%	19% to 28%	29%	23%	18%
Underlying share price of the investee ⁽³⁾	A\$0.096	\$19.42	\$1.85	C\$10.16	C\$6.48	GBP0.70	\$6.18
Conversion price	A\$0.25	\$30.50	\$1.90	C\$3.52 to C\$17.32	C\$10.82 to C\$19.67	GBP0.90	\$6.76
Exchange rate (C\$ - \$)	-	-	-	0.7279	0.7279	-	-
Exchange rate (A\$ - \$)	0.6431	-	-	-	-	-	-
Exchange rate (GBP - \$)	-	-	-	-	-	1.3459	-

⁽¹⁾ Market price volatility for listed issuers is derived from the volatility of the issuer's quoted share price, and for unlisted issuers is derived based on the volatility of quoted market prices for similar instruments.

⁽²⁾ Modelled price volatility is derived from market price volatility by excluding days with no trading volume and incorporating a calibration adjustment used to equate the initial estimated fair value of the debenture to the purchase consideration.

⁽³⁾ Underlying share price for listed issuers is based on the quoted market share price. Underlying share price for unlisted issuers is estimated using other third-party evidence and relevant valuation techniques.

⁽⁴⁾ Several convertible debentures issued on various dates.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments (continued):

(c) Investments in convertible debentures (continued):

August 31, 2024	Challenger	Contango	Gold Royalty	IsoEnergy (4)	Los Andes ⁽⁴⁾	Moxico	NexGen
Expected life (years)	2.0	3.7	4.3	1.0 to 3.3	1.8 to 3.0	4.9	4.1
Market price volatility ⁽¹⁾	69%	66%	60%	67% to 81%	40% to 43%	60%	61%
Modeled price volatility ⁽²⁾	57%	45%	35%	60% to 65%	32% to 38%	34%	38%
Risk-free interest rate	3.9%	3.8%	3.8%	3.2% to 3.6%	3.3% to 3.5%	3.8%	3.8%
Coupon interest rate	9.0%	9.0%	10.0%	8.5% to 10.0%	8.0%	11.0%	9.0%
Expected dividend yield	-%	-%	-%	-%	-%	-%	-%
Credit spread	29%	30%	21%	18% to 27%	29%	23%	18%
Underlying share price of the investee ⁽³⁾	A\$0.05	\$21.52	\$1.31	C\$3.05	C\$9.49	GBP0.60	\$6.03
Conversion price	A\$0.25	\$30.50	\$1.90	C\$0.88 to C\$4.33	C\$10.82 to C\$19.67	GBP0.90	\$6.76
Exchange rate (C\$ - \$)	-	-	-	0.7412	0.7412	-	-
Exchange rate (A\$ - \$)	0.6765	-	-	-	-	-	-
Exchange rate (GBP - \$)	-	-	-	-	-	1.3127	-

⁽¹⁾ Market price volatility for listed issuers is derived from the volatility of the issuer's quoted share price, and for unlisted issuers is derived based on the volatility of quoted market prices for similar instruments.

⁽²⁾ Modelled price volatility is derived from market price volatility by excluding days with no trading volume and incorporating a calibration adjustment used to equate the initial estimated fair value of the debenture to the purchase consideration.

⁽³⁾ Underlying share price for listed issuers is based on the quoted market share price. Underlying share price for unlisted issuers is estimated using other third-party evidence and relevant valuation techniques.

⁽⁴⁾ Several convertible debentures issued on various dates.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

4. Investments (continued):

(c) Investments in convertible debentures (continued):

For the nine months ended May 31, 2025, the Company has recorded interest income on convertible debentures of \$13,873 (May 31, 2024 - \$10,335). During the nine months ended May 31, 2025, the Company received interest payments of \$11,529 of which \$8,374 was settled in cash and \$3,155 was settled in common shares (May 31, 2024 - received \$7,703 of which \$5,752 was in cash and \$1,951 in common shares).

For the nine months ended May 31, 2025, the Company recorded interest income on cash balances of \$52 (May 31, 2024 - \$194) of which \$52 was received (May 31, 2024 - \$194).

5. Interest expense:

Interest expense consist of the following:

	Three months ended			 Nine months ende		is ended	
		May 31, 2025		May 31, 2024	May 31, 2025		May 31, 2024
Interest expense on borrowings (note 8) Interest expense on lease liabilities	\$	346 5	\$	626 2	\$ 1,170 6	\$	1,170 9
	\$	351	\$	628	\$ 1,176	\$	1,179

6. Accounts payable and accrued liabilities:

Accounts payable and accrued liabilities consist of the following:

	May 31, 2025	A	ugust 31, 2024
Accounts payable Accrued liabilities Taxation liabilities Due to related parties (note 7)	\$ 46 94 3 694	\$	6 190 28 882
	\$ 837	\$	1,106

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

7. Related party transactions:

The following related party transactions were conducted in the normal course of business:

	Three months ended			 Nine months endeo			
		May 31, 2025		May 31, 2024	May 31, 2025		May 31, 2024
Management fees Directors' fees	\$	471 25	\$	463 25	\$ 1,415 74	\$	1,362 63
	\$	496	\$	488	\$ 1,489	\$	1,425

As of May 31, 2025, receivables include an amount of \$751 due from a director of the Company relating to amounts advanced to fund the exercise of share options in the Company (note 3). This amount is non-interest-bearing and has no fixed repayment terms.

As of May 31, 2025, accounts payable and accrued liabilities include an amount of \$694 (August 31, 2024 - \$882) due to directors and officers of the Company, and/or companies controlled by these directors, relating to fees and expense reimbursement (note 6). These amounts are unsecured, non-interest-bearing, and have no fixed repayment terms.

As of May 31, 2025, the Company holds equity investments and convertible debentures in Gold Royalty, Moxico, and NexGen, companies with a common director, and IsoEnergy, a company controlled by NexGen. The estimated fair value of equity investments and convertible debentures of these related companies, on May 31, 2025, is \$251,437 (August 31, 2024 - \$215,816). Establishment fee income for the nine months ended May 31, 2025, is \$900 (May 31, 2024 - \$3,000), and interest income on convertible debentures is \$10,670 (May 31, 2024 - \$4,507, including Los Andes) from these related companies.

Corom Pty Ltd. ("Corom"), a company controlled by a relative of a director of the Company and a significant shareholder of the Company, purchased 553,022 common shares of the 2,142,857 common shares issued by the Company in a private placement on September 18, 2024 (note 9(a)).

A director of the Company purchased 485,714 common shares of the 2,142,857 common shares issued by the Company in a private placement on September 18, 2024 (note 9(a)) and became a significant shareholder.

During the nine months ended May 31, 2025, the Company sold \$556 of investments in shares to a member of management, who is also a director. The transaction was settled in cash, resulting in a realized gain of \$6.

During the nine months ended May 31, 2025, a director of the Company exercised 300,000 options at C\$3.00 per share and a director of the Company exercised 800,000 options at C\$6.40 per share (note 9(c)).

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

8. Borrowings:

Borrowings comprise:

	May 31, 2025		August 31, 2024	
Margin loan, secured	\$	26,540	\$ 31,626	

The movement in borrowings for the nine months ended May 31, 2025 and 2024 consist of the following:

	Nine months ended			
	May 31,			
	2025		2024	
Balance, beginning of the period	\$ 31,626	\$	-	
Margin loan drawdowns	35,055		-	
Bank loan drawdowns	-		22,500	
Bank loan transaction costs	-		(325)	
Amortization of transaction costs	-		15 2	
Interest expense	1,170		1,018	
Margin loan repayments	(40,097)		-	
Interest expense payments	(1,214)		(636)	
Balance, end period	\$ 26,540	\$	22,709	

The margin loan has an annual interest rate calculated as a blended rate based on tiers with spreads from 0.5% to 1.5% over the benchmark rate of the US Fed Funds Effective Overnight Rate. The effective interest rate on May 31, 2025, was 5.1% (August 31, 2024 – 6.1%). Interest is accrued daily, and monthly interest is added to the loan account on the third business day of the following month.

The margin loan has no fixed repayment term. The loan is secured over the cash and securities held by the brokerage firm, with a value of \$97,333 on May 31, 2025 (August 31, 2024 - \$89,671). Margin requirements are calculated by the brokerage firm and advised daily. If the loan's value exceeds the maintenance margin requirement, a portion of the margin loan must be repaid, or additional collateral must be provided. The brokerage firm has the right to liquidate securities within the portfolio to bring the loan back into compliance with margin requirements. The loan complied with the margin requirements on May 31, 2025, and August 31, 2024.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

8. Borrowings (continued):

The maximum bank loan amount was drawn down on December 13, 2023, and fully repaid by July 2, 2024. Transaction costs due to be expensed over the term of the loan under the effective interest rate method were fully expensed on repayment of the loan.

9. Share capital:

(a) Common shares:

As of January 15, 2025 the Company completed a share consolidation of the Company's issued and outstanding shares (the "Share Consolidation") at a consolidation ratio of ten (10) pre-consolidation common shares for every one (1) post-consolidation common share. All disclosures of common shares, per common share data and data related to stock options reflect this Share Consolidation for all periods presented.

Authorized:

500,000,000 common shares with a par value of C\$0.01 each, amended from 5,000,000,000 common shares with a par value of C\$0.001 before the Share Consolidation

Issued and outstanding:

49,824,250 common shares at May 31, 2025 (August 31, 2024 – 45,548,550).

The continuity of the Company's issued, fully paid and outstanding common shares is as follows:

	Nine month	ns ended
	May 31,	May 31,
	2025	2024
Balance, beginning of period	45,548,550	45,035,651
Issued by private placement	2,142,857	-
Issued on exercise of share options	1,136,600	-
Issued in settlement of dividend	1,135,253	665,296
Issued on rounding up on share consolidation	3	-
Repurchased through NCIB and canceled	(139,013)	(126,129)
Balance, end of period	49,824,250	45,574,818

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

9. Share capital (continued):

(a) Common shares (continued):

Share transactions during the nine months ended May 31, 2025, were as follows:

- 2,142,857 common shares of the Company were issued on September 18, 2024 at C\$7.00 per share for gross proceeds of \$11,025 through a non-brokered private placement. The private placement included shares purchased by two related parties: Corom and a director of the Company (note 7). BBFIT Investments Pte Ltd., a significant shareholder of the Company, purchased 397,142 common shares of the 2,142,857 shares issued.
- 1,136,600 common shares of the Company were issued as fully paid shares from the exercise of share options:
 - 115,860 common shares issued on October 11, 2024 from the exercise of share options at C\$3.00 per share.
 - 15,000 common shares issued on October 23, 2024 from the exercise of share options at C\$5.50 per share.
 - 97,421 common shares issued on November 11, 2024 from the exercise of share options at C\$3.00 per share.
 - 86,719 common shares issued on January 31, 2025 from the exercise of share options at C\$3.00 per share.
 - 800,000 common shares issued on March 4, 2025 from the exercise of options at C\$6.40 per share.
 - 21,600 common shares issued on March 4, 2025 from the exercise of options at C\$6.40 per share.
- \$4,346 was received in cash, and \$3,455 was transferred from share-based reserves to share capital for the issue of the 1,136,600 common shares on the exercise of the share options.
- 1,135,253 shares of the Company were issued on November 14, 2024, as fully paid shares for the settlement of dividends of C\$0.21 per share, based on a share price of C\$7.00. \$5,653 was transferred from retained earnings to share capital.
- 139,013 shares of the Company, repurchased through the Normal Course Issuer Bid ('NCIB") were canceled: 750 shares on November 4, 2024; 11,700 shares on November 14, 2024; 2,307 shares on November 29, 2024; 6,900 shares on February 28, 2025 and 117,356 shares on May 30, 2025.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

9. Share capital (continued):

(a) Common shares (continued):

The total cost of the shares canceled, including commission, was \$634 an average cost of C\$6.45 per share. \$563 representing the average issue price of the canceled shares, was transferred from the treasury share reserve to share capital. The remaining \$71 was transferred from the treasury share reserve to retained earnings.

• All shares repurchased under the NCIB were cancelled as at May 31, 2025 and no shares were held in treasury.

Share transactions during the nine months ended May 31, 2024, were as follows:

- 665,296 shares of the Company were issued on November 16, 2023, as fully paid shares for the settlement of dividends of C\$0.19 per share, based on a share price of C\$6.50. \$3,144 was transferred from retained earnings to share capital.
- 126,129 shares of the Company, repurchased through the Normal Course Issuer Bid ("NCIB") were canceled: 17,850 shares on November 6, 2023; 23,381 shares on November 20, 2023; 27,509 shares on February 29, 2024 and 57,389 shares on May 31, 2025.

The total cost of the shares canceled, including commission, was \$752 an average cost of C\$7.54 per share. \$493, representing the average issue price of the canceled shares, was transferred from the treasury share reserve to share capital. The remaining \$259 was transferred from the treasury share reserve to retained earnings.

- All shares repurchased under the NCIB were cancelled as at May 31, 2024 and no shares were held in treasury.
- (b) Warrants:

There were no warrants outstanding at May 31, 2025 and 2024.

(c) Stock options:

The Company's new incentive stock option plan ("2022 Option Plan") was approved by the shareholders of the Company at the Annual General Meeting on December 22, 2022, under which, it is authorized to grant options to executive officers, directors, employees, and consultants to acquire up to 10% of the outstanding issued common shares, subject to certain limitations in respect of the maximum number of common shares issuable to insiders. The 2022 Option Plan allows for the option price at the time each option is granted to be not less than the volume weighted average trading price of the common shares on the TSX for the 5-days immediately preceding the grant date. The 2022 Option Plan provides participants with a cashless exercise alternative. Options granted under the 2022 Option Plan will have a term not to exceed 5-years. Vesting is determined at the discretion of the Board of Directors and in accordance with the policies of the TSX.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

9. Share capital (continued):

(c) Stock options (continued):

Options granted under the Company's previous stock option plan ("Old Option Plan") will continue to be governed by the Old Option Plan.

The number of options outstanding at May 31, 2025, was 2,728,400 with a weighted average exercise price of C6.40 (August 31, 2024 – 3,865,000 with a weighted average exercise price of C6.13).

No stock options were issued during the nine months ended May 31, 2025, nor in the year ended August 31, 2024.

The continuity of the Company's stock options is as follows:

	Nine months	s ended
	May 31, 2025	May 31, 2024
Balance, beginning of period Exercised	3,865,000 (1,136,600)	3,865,000 -
Balance, end of period	2,728,400	3,865,000

1,136,600 options of the Company were exercised during the nine months ended May 31, 2025, as follows:

- 115,860 options at C\$3.00 per share were exercised by a director on October 10, 2024.
- 15,000 options at C\$5.50 per share were exercised by a consultant on October 23, 2024.
- 97,421 options at C\$3.00 per share were exercised by a director on November 11, 2024.
- 86,719 options at C\$3.00 per share were exercised by a director on January 31, 2025.
- 800,000 options at C\$6.40 per share were exercised by a director on March 3, 2025.
- 21,600 options at C\$6.40 per share were exercised by an officer on March 4, 2025.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

9. Share capital (continued):

(c) Stock options (continued):

A summary of the Company's outstanding options at May 31, 2025, is as follows:

Exercise price C\$	outstanding	exercisable	Expiry date
6.40	2,728,400	2,728,400	February 28, 2027
	2,728,400	2,728,400	

A summary of the Company's outstanding options at August 31, 2024, is as follows:

Number of options							
outstanding	exercisable	Expiry date					
300,000	300,000	February 3, 2025					
15,000	15,000	February 18, 2025					
3,550,000	3,550,000	February 28, 2027					
3 865 000	3 865 000						
	outstanding 300,000 15,000	outstanding exercisable 300,000 300,000 15,000 15,000 3,550,000 3,550,000					

(d) Normal Course Issuer Bid ("NCIB"):

The NCIB, a Company share repurchase program, was renewed for 12-months from November 22, 2024. Repurchases are conducted by a third-party broker. The current NCIB allows for the repurchase of up to 1,760,000 shares.

During the nine months ended May 31, 2025, there were repurchases of 139,013 shares for cash of \$634 (May 31, 2024 - repurchases of 126,129 shares for cash of \$752).

(e) Dividend:

On October 11, 2024, the Company declared a dividend of C\$0.21 per share to all shareholders of record on November 4, 2024. The dividend of \$7,158 was paid on November 14, 2024, with \$1,505 paid in cash and \$5,653 settled by the issue of 1,135,253 shares under the Company's Dividend Reinvestment Plan ("DRIP").

On October 11, 2023, the Company declared a dividend of C\$0.19 per share to all shareholders of record on November 6, 2023. The dividend of \$6,218 was paid on November 16, 2023, with \$3,074 paid in cash and \$3,144 settled by the issue of 665,296 shares under the Company's DRIP.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

10. Basic and diluted net income per share:

The basic net income per share is calculated using the weighted average number of common issued shares less the weighted average number of shares repurchased and held in treasury to derive the weighted average number of issued and outstanding shares as follows:

	Three mo	nths ended	Nine mo	onths ended
	May 31,	May 31,	May 31,	May 31,
	2025	2024	2025	2024
Weighted average number of				
issued shares	49,033,285	45,632,207	48,909,877	45,469,773
Weighted average number of				
shares issued and held in treasury	66,894	28,257	24,115	24,112
Weighted average number of				
issued and outstanding shares	48,966,391	45,603,950	48,885,762	45,445,661

Diluted net income per share was calculated using the weighted average number of common shares issued and outstanding, adjusted for the dilutive effect of 2,728,400 stock options (May 31, 2024 - 3,865,000 stock options).

11. Financial instruments and risk management:

The Company provides disclosures that enable users to evaluate (a) the significance of financial instruments for the entity's financial position and performance; and (b) the nature and extent of risks arising from financial instruments to which the entity is exposed during the year and at the date of the Statement of Financial Position, and how the entity manages these risks.

The following table summarizes the carrying value of financial assets and liabilities of the Company as at May 31, 2025, and August 31, 2024:

	May 31, 2025	I	August 31, 2024
Estimated fair value through profit and loss: Investments	\$ 313,503	\$	279,332
Amortized cost:			
Cash and cash equivalents	1,913		1,094
Receivables	5,291		2,196
Accounts payable and accrued liabilities	837		1,106
Borrowings	26,540		31,626
Lease liabilities	514		126

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

11. Financial instruments and risk management (continued):

As at May 31, 2025, and August 31, 2024, financial instruments that are not measured at estimated fair value on the balance sheet are represented by cash, receivables, accounts payable and accrued liabilities, borrowings and lease liabilities. The fair value of these financial instruments approximates the carrying value due to their short-term nature and the fair values are estimated using Level 2 inputs.

Financial instruments that are recognized on the balance sheet at fair value can be classified in a hierarchy that is based on the relative reliability of the inputs used to estimate the fair value:

- Level 1 quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (*i.e.*, as prices) or indirectly (*i.e.*, derived from prices); and
- Level 3 inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Level 3 financial instruments consist of convertible debentures issued by unlisted companies and common shares issued by unlisted companies. The Company uses other third-party evidence and relevant valuation techniques to estimate the share price and uses quoted market prices for similar instruments to derive volatility and credit spread to value these Level 3 investments.

May 31, 2025	Level 1	Level 2	Level 3
Investments at estimated fair value	\$ 98,435	\$ 164,530	\$ 50,538
August 31, 2024	Level 1	Level 2	Level 3
Investments at estimated fair value	\$ 91,607	\$ 169,563	\$ 18,162

The Company's financial assets measured at FVTPL are as follows:

There were asset transfers from Level 2 to Level 1 of \$9,690 due to the conversion of debentures into common shares in the nine months ended May 31, 2025. There were asset transfers from Level 2 to Level 1 of \$73,247 due to the conversion of debentures into common shares during the year ended August 31, 2024.

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

11. Financial instruments and risk management (continued):

The movement in Level 3 investments for the nine months ended May 31, 2025, consist of the following:

	 Nine mont	hs end	ded May 3′	1, 20	25	
	Shares	Convertible debentures			Total	
Balance, beginning of period	\$ -	\$	18,162	\$	18,162	
Additions	1,080		30,000		31,080	
Proceeds from disposals	(563)		-		(563)	
Realized gain	6		-		6	
Unrealized gain	26		1,827		1,853	
Balance, end of period	\$ 549	\$	49,989	\$	50,538	

The movement in Level 3 investments for year ended August 31, 2024 consist of the following:

		Year ended August 31, 2024						
	Shares		Convertible debentures			Total		
Balance, beginning of period Additions Unrealized (loss)	\$	-	\$	- 20,000 (1,838)	\$	- 20,000 (1,838)		
Balance, end of period	\$	-	\$	18,162	\$	18,162		

The total unrealized gain recognized in Condensed Interim Consolidated Statements of Loss and Comprehensive Loss for the nine months ended May 31, 2025, in respect of Level 3 investments in convertible debentures and common shares was \$1,853 (May 31, 2024 - nil). The estimated fair value would increase (decrease) if the estimated share price was higher (lower); the estimated volatility was higher (lower), or the credit spread was lower (higher).

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

11. Financial instruments and risk management (continued):

A one percentage point increase or decrease in the unobservable inputs used to estimate the fair value of the Level 3 investments of estimated share price, volatility, or credit spread would have the following impact on the estimated fair value at May 31, 2025:

Convertible debentures: Share price Volatility Credit spread	1% :	1% increase		
	\$	256 86 (117)	\$	(256) (86) 236
Common shares: Share Price		5		(5)

Financial risks:

The Company has exposure to the following risks from its use of financial instruments:

- Credit risk;
- Liquidity risk;
- Interest and foreign exchange risk; and
- Market price risk.
- (a) Credit risk:

Credit risk is the risk of potential loss the Company may incur if a counterparty to a financial instrument fails to meet its contractual obligations. The Company's credit risk is primarily attributable to its liquid financial assets, including cash and investments. The Company has limited exposure to credit risk associated with cash, as it only deposits its cash on demand with high-credit quality financial institutions. The Company's equity investments are settled and paid for upon delivery using an approved broker. The risk of default is considered minimal, as delivery of securities sold is made once the broker has received payment and payment on a purchase is received by the broker. The trade will fail if either party fails to meet its obligations. The Company's credit risk related to convertible debentures is associated with the risk that these third parties will not perform their underlying obligations. The Company mitigates its credit risk by only investing and providing loans where they have a detailed knowledge of the investee's operations and business strategy. The Company has convertible debentures invested in seven companies at May 31, 2025, consisting of 36% NexGen, 23% Moxico, 16% Gold Royalty, 8% Contango, 6% Challenger, 6% IsoEnergy, and 5% Los Andes (August 31, 2024 - 41% NexGen, 15% Gold Royalty, 13% IsoEnergy, 10% Moxico, 9% Contango, 6% Challenger and 6% Los Andes).

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

11. Financial instruments and risk management (continued):

(b) Liquidity risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations when they become due. The Company has ensured, as far as reasonably possible, it will have sufficient working capital in order to meet short-term business requirements, after taking into account cash flows from operations and the Company's holdings of cash. Historically, the Company's primary source of financing has been the issuance of equity securities for cash, through private placements. The Company has also obtained liquidity through arranging secured bank and other margin loans.

The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity, bank or other financing. As of May 31, 2025, the Company had no significant contractual obligations other than those included in accounts payable, accrued liabilities, borrowings and lease liabilities.

(c) Interest and foreign exchange risk:

The Company is subject to normal risks, including fluctuations in interest rates and foreign exchange rates. While the Company manages its operations to minimize exposure to these risks, it has not entered into any derivatives or contracts to hedge or otherwise mitigate this exposure.

At May 31, 2025, the Company is exposed to limited interest rate risk as it earns relatively low interest on its cash balance due to modest interest rates on United States dollars, Canadian dollars ("C\$") and Australian dollars (A\$). The Company is exposed to interest rate risk on its borrowings arising from movements in United States Federal Funds Effective Overnight Rate.

The Company has assets and liabilities denominated in foreign currencies. The Company's exposure to exchange rate fluctuations arises mainly from foreign currency fluctuations against the United States dollar functional currency.

The Company is exposed to foreign currency risk due to fluctuations related to cash, prepayments and deposits, investments, and accounts payable and accrued liabilities and lease liabilities that are denominated in Canadian (C\$); Hong Kong ("HK\$"); Australian ("A\$") dollars; and British Pounds ("GBP").

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

11. Financial instruments and risk management (continued):

(c) Interest and foreign exchange risk (continued):

The United States dollar equivalent of assets (liabilities) denominated in the foreign currencies are as follows:

May 31, 2025		C\$		GBP		HK\$		A\$		Total
Cash	\$	380	\$	-	\$	19	\$	478	\$	877
Prepayments and deposits		1		-		56		-		57
Investments		76,087		549		-		20,739		97,375
Accounts payable and		(00)		(10)		(24)				(4 4 4)
accrued liabilities		(92)		(18)		(34)		-		(144)
Lease liabilities		-		-		(514)		-		(514)
Net assets (liabilities)	\$	76,376	\$	531	\$	(473)	\$	21,217	\$	97,651
August 31, 2024		C\$		GBP		HK\$		A\$		Total
Cash	\$	285	\$	_	\$	21	\$	_	\$	306
Prepayments and deposits	Ψ	1	Ψ	-	Ψ	62	Ψ	-	Ψ	63
Investments		67,317		-		-		22,465		89,782
Accounts payable and										-
accrued liabilities		(153)		(8)		(44)		-		(205)
Lease liabilities		-		-		(127)		-		(127)
Net assets (liabilities)	\$	67,450	\$	(8)	\$	(88)	\$	22,465	\$	89,819

Based on the above net exposure as at May 31, 2025, and assuming all other variables remain constant, a 2% depreciation or appreciation of the C\$, HK\$, A\$ and GBP against the United States dollar would result in an increase or decrease of approximately \$2,000 (August 31, 2024 - \$1,800) in the Company's net income and comprehensive income.

(d) Market price risk:

Market price risk is the risk that the estimated fair value of an investment measured at FVTPL will fluctuate because of changes in market prices (other than those arising from foreign currency risk or interest rate risk). The Company's investments at estimated fair value of public entities are subject to price risk. A 5% increase and a 5% decrease in the value of the individual equity market prices in public entities, or individual equity prices in listed and unlisted entities, which are used as equivalent equity instruments for the valuation of non-traded investments, would result in an increase of approximately \$13,000 and a decrease of approximately \$10,100, respectively, in the value of investments and unrealized loss for the nine months ended May 31, 2025 increase of approximately \$10,100 and decrease of approximately \$10,600, respectively, in the value of investments and unrealized gain for the year ended August 31, 2024).

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

12. Capital management:

The Company considers the items in shareholders' equity as capital. The Company's objectives when managing capital are to maintain financial strength and to protect its ability to meet its future liabilities, to continue as a going concern, to maintain creditworthiness and to maximize returns for shareholders over the long-term.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

The Company's objectives when managing capital are:

- (a) to maintain the Company's ability to make new investments by allowing it to respond to economic changes and/or the marketplace;
- (b) to maintain growth of shareholders' equity; and
- (c) to continue taking a conservative approach towards financial leverage and management of financial risks.

The Company reviews its capital structure on an on-going basis and makes adjustments in light of changes in economic conditions and the risk characteristics of its underlying investments. The Company has adjusted or maintained its level of capital by raising additional capital through equity financings. The Company is not subject to externally imposed capital requirements.

13. Supplemental disclosure with respect to cash flows:

Significant non-cash transactions in the nine months ended May 31, 2025, and 2024, were:

	 Nine mon	ths er	nded
	May 31, 2025		May 31, 2024
Investments received for settlement of establishment fees (note 4)	\$ 300	\$	2,100
Investments received for settlement of interest receivable (note 4)	3,155		1,951
Investments received on conversion of debentures (note 4)	9,690		77,445
Transfer from retained earnings to share capital for shares issued under the DRIP (note 9(e))	5,653		3,144
Transfer from retained earnings to share capital for shares Issued for options exercised (note 9(a))	3,455		-

Notes to Condensed Interim Consolidated Financial Statements (Amounts expressed in thousands of United States dollars, unless otherwise indicated)

Three and nine months ended May 31, 2025 and 2024

14. Segmented information:

An operating segment is defined as a component of the Company that engages in business activities from which it may earn revenues and incur expenses, whose operating results are reviewed regularly by the Company's executive management, and for which discrete financial information is available. The Company has determined that it currently has one operating segment, being the selection, acquisition, and management of investments. The Company's corporate head office incurs nominal costs that are incidental to the activities of the Company and therefore does not meet the definition of an operating segment.